off
Amgen, Allergan achieve endpoints in ABP 215 biosimilar candidate study
In phase 3 trials, Amgen and Allergan’s biosimilar ABP 215 proved that it works similarly to Avastin, both in terms of outcomes and reported adverse events.
Posted On Sep 24 2015
